anti-MAGE-A4 TCR NK cell therapy (Zelluna Immunotherapy)

N/A

Report date: 2025/03/14 18:13:45

Base Information

Drug Nameanti-MAGE-A4 TCR NK cell therapy (Zelluna Immunotherapy)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionMelanoma-associated antigen 4 modulatorsHistocompatibility antigens class I modulators

TargetsHistocompatibility antigens class IMelanoma-associated antigen 4

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNorway

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesZelluna Immunotherapy AS

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A